Immune subtraction for improved resolution in serum protein immunofixation electrophoresis and antibody isotype determination in a patient with autoantibody

[1]  Hongyan Xu,et al.  Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas. , 2020, Laboratory medicine.

[2]  Gurmukh Singh.  Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies. , 2020, The journal of applied laboratory medicine.

[3]  R. Bollag,et al.  Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains. , 2020, Laboratory medicine.

[4]  R. Bollag,et al.  Challenges in Interpreting Multiple Monoclonal Bands on Serum Protein Electrophoresis and Serum Immunofixation Electrophoresis: An Illustrative Case Report. , 2019, The journal of applied laboratory medicine.

[5]  Gurmukh Singh.  Concentrations of Serum Free Light Chains in Kappa and Lambda Lesions in Light-Chain Myelomas. , 2018, Laboratory medicine.

[6]  J. Cerhan,et al.  Long‐Term Follow‐up of Monoclonal Gammopathy of Undetermined Significance , 2018, The New England journal of medicine.

[7]  Gurmukh Singh.  Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results , 2017, Journal of clinical medicine research.

[8]  Gurmukh Singh.  Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio , 2016, Journal of clinical medicine research.

[9]  Gurmukh Singh.  Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies:  High False-Positive Rate. , 2016, American journal of clinical pathology.

[10]  S. Rajkumar,et al.  Smoldering multiple myeloma. , 2015, Blood.

[11]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[12]  N. Harris,et al.  The heavy chain diseases: clinical and pathologic features. , 2014, Oncology.

[13]  R. Lewis,et al.  An Update on Monoclonal Gammopathy and Neuropathy , 2012, Current Neurology and Neuroscience Reports.

[14]  Hartmut Goldschmidt,et al.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. , 2011, Blood.

[15]  J. Tate,et al.  Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. , 2009, The Clinical biochemist. Reviews.

[16]  T. Therneau,et al.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.

[17]  G. Shaw.  Nonsecretory plasma cell myeloma--becoming even more rare with serum free light-chain assay: a brief review. , 2009, Archives of pathology & laboratory medicine.

[18]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[19]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.